SAN DIEGO, Feb. 7, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:The 15th Annual BIO CEO & Investor Conference Date:
Tuesday, February 12, 2013Time:
2:00 p.m. Eastern TimeLocation:
The Waldorf Astoria, New York2013 Leerink Swann Global Healthcare Conference Date:
Wednesday, February 13, 2013Time:
11:30 a.m. Eastern Time Location:
The Waldorf Astoria, New YorkThe BIO CEO & Investor Conference presentation will be webcast live. To access the webcast, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
Orexigen Contact: McDavid Stilwell
VP, Corporate Communications and Business Development
Media Contact: Denise Powell
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved